|
ACET | Adicet Bio, Inc. |
|
|
ACET | Adicet Bio, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.29 |
| Leverage | 22.31% |
| Market Cap | $ 375.5m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -114.7m |
| Margin | 32845.37% |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.